Right to Treat Act
- Sponsor
- Sen. Johnson, Ron [R-WI]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Mar 19, 2026
Bottom line
The bill aims to significantly limit federal oversight of medical practice and drug prescription, shifting authority towards states and individual practitioners, while explicitly carving out certain controversial medical interventions from its scope.
What it actually does
This bill, the "Right to Treat Act," explicitly states that no federal agency within the Department of Health and Human Services, including the FDA, NIH, and CDC, has the authority to regulate the practice of medicine. It also prohibits federal restrictions on the off-label prescription or disbursement of FDA-approved drugs or those available under emergency use authorizations.
Proponents argue
Proponents argue this bill restores the traditional authority of states and medical professionals over the practice of medicine, preventing federal overreach into clinical decisions. They contend it empowers doctors to use their best judgment, including prescribing FDA-approved drugs for unapproved uses, without fear of federal interference, thereby enhancing patient access to potentially life-saving treatments.
Opponents contend
Opponents would likely argue that this bill undermines critical federal safeguards designed to protect public health and patient safety. They might contend that removing federal oversight from the "practice of medicine" could lead to inconsistent standards, expose patients to unproven or harmful treatments, and weaken the FDA's ability to ensure drug efficacy and safety, particularly concerning off-label uses.
The bill text is very short and can be read quickly, but its implications are far-reaching and require significant consideration beyond the text itself.
Section 2(a)(1)
Federal Agencies Prohibited from Regulating Medical Practice
This section explicitly states that federal agencies, including the Food and Drug Administration (FDA), National Institutes of Health (NIH), and Centers for Disease Control and Prevention (CDC), are not allowed to regulate the "practice of medicine." This aims to draw a clear line between federal authority over drug and device approval and state authority over how those drugs and devices are used by medical professionals.
Supporters argue
Supporters argue this provision restores the traditional balance of power, affirming that medical practice is primarily a state responsibility. They believe it protects the doctor-patient relationship from federal interference and allows for more innovative and individualized patient care.
Critics contend
Critics would contend that this provision could create regulatory gaps, potentially allowing unsafe or ineffective practices to proliferate if states do not adequately fill the void. They might argue that federal agencies play a crucial role in setting national standards and protecting public health, especially in areas like infectious disease control or drug safety.
Tradeoffs
The tension lies between federal standardization and oversight for public health versus state-level control and individual practitioner autonomy in medical practice. It trades potential national consistency for localized flexibility.
Section 2(a)(2)
Federal Non-Restriction of Off-Label Drug Prescriptions
This section prevents any federal law, rule, regulation, or policy from prohibiting or restricting the prescription or disbursement of an FDA-approved drug for a use not specifically approved by the FDA (known as "off-label" use). It also extends this protection to drugs available under emergency use authorizations or expanded access programs.
Section 2(b)
Exclusions from Scope of Authorities
This section clarifies that the Act does not override or affect any existing federal laws, rules, regulations, or policies that restrict specific medical interventions, including abortion, assisted suicide, euthanasia, mercy killing, coercive family planning, female genital mutilation, or gender transition medical interventions. This ensures that the bill's primary intent to limit federal regulatory power does not inadvertently legalize or deregulate these specific practices at the federal level.